Viracta Therapeutics, Inc. (VIRX)

0,8283 -0,0187 (-2,21%) Börsenschluss: 04:00PM EDT

Viracta Therapeutics, Inc.

2533 South Coast Highway 101
Suite 210
Cardiff, CA 92007
United States
858 400 8470
https://www.viracta.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 40

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Mark Andrew Rothera	CEO, President & Director	365,03k	N/A	1963
Dr. Susan Perrine M.D.	Scientific Founder and Consultant	N/A	N/A	N/A
Dr. Ronald J. Berenson M.D.	Co-Founder and Consultant	N/A	N/A	1952
Mr. George Hillman	Co-Founder	N/A	N/A	N/A
Dr. Thalia Papayannopoulou M.D.	Co-Founder	N/A	N/A	N/A
Dr. Robert M. Williams Ph.D.	Co-Founder	N/A	N/A	1955
Dr. Douglas V. Faller M.D., Ph.D.	Scientific Founder & Chairman of Scientific Advisory Board	N/A	N/A	N/A
Ms. Melody Burcar CPA, M.B.A.	Senior VP of Finance, Interim Principal Financial Officer & Interim Principal Accounting Officer	N/A	N/A	1983
Dr. Ayman El-Guindy	Chief Scientific Officer	N/A	N/A	N/A
Mr. Stewart M. Brown	Senior VP of Legal Affairs & General Counsel	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.

Corporate Governance

Viracta Therapeutics, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.